» Articles » PMID: 29042669

RNA Editing by ADAR1 Regulates Innate and Antiviral Immune Functions in Primary Macrophages

Overview
Journal Sci Rep
Specialty Science
Date 2017 Oct 19
PMID 29042669
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

ADAR1-dependent A-to-I editing has recently been recognized as a key process for marking dsRNA as self, therefore, preventing innate immune activation and affecting the development and resolution of immune-mediated diseases and infections. Here, we have determined the role of ADAR1 as a regulator of innate immune activation and modifier of viral susceptibility in primary myeloid and lymphoid cells. We show that ADAR1 knockdown significantly enhanced interferon, cytokine and chemokine production in primary macrophages that function as antiviral paracrine factors, rendering them resistant to HIV-1 infection. ADAR1 knockdown induced deregulation of the RLRs-MAVS signaling pathway, by increasing MDA5, RIG-I, IRF7 and phospho-STAT1 expression, an effect that was partially rescued by pharmacological blockade of the pathway. In summary, our results demonstrate a role of ADAR1 in regulating innate immune function in primary macrophages, suggesting that macrophages may play an essential role in disease associated to ADAR1 dysfunction. We also show that viral inhibition is exclusively dependent on innate immune activation consequence of ADAR1 knockdown, pointing towards ADAR1 as a potential target to boost antiviral immune response.

Citing Articles

RNA-binding proteins as therapeutic targets in cancer.

Jungfleisch J, Gebauer F RNA Biol. 2025; 22(1):1-8.

PMID: 40016176 PMC: 11869776. DOI: 10.1080/15476286.2025.2470511.


Past, Present, and Future of RNA Modifications in Infectious Disease Research.

Pan X, Bruch A, Blango M ACS Infect Dis. 2024; 10(12):4017-4029.

PMID: 39569943 PMC: 11651297. DOI: 10.1021/acsinfecdis.4c00598.


ADAR-Mediated A>I(G) RNA Editing in the Genotoxic Drug Response of Breast Cancer.

Bernal Y, Duran E, Solar I, Sagredo E, Armisen R Int J Mol Sci. 2024; 25(13).

PMID: 39000531 PMC: 11242177. DOI: 10.3390/ijms25137424.


Lung Gene Expression Suggests Roles for Interferon-Stimulated Genes and Adenosine Deaminase Acting against RNA-1 in Pathologic Responses to Diisocyanate.

Wisnewski A, Liu J Chem Res Toxicol. 2024; 37(3):476-485.

PMID: 38494904 PMC: 11748834. DOI: 10.1021/acs.chemrestox.3c00325.


Antiviral Defence Mechanisms during Early Mammalian Development.

Mueller F, Witteveldt J, Macias S Viruses. 2024; 16(2).

PMID: 38399949 PMC: 10891733. DOI: 10.3390/v16020173.


References
1.
Crow Y, Chase D, Lowenstein Schmidt J, Szynkiewicz M, Forte G, Gornall H . Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am J Med Genet A. 2015; 167A(2):296-312. PMC: 4382202. DOI: 10.1002/ajmg.a.36887. View

2.
Clerzius G, Gelinas J, Gatignol A . Multiple levels of PKR inhibition during HIV-1 replication. Rev Med Virol. 2011; 21(1):42-53. DOI: 10.1002/rmv.674. View

3.
Samuel C . Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral. Virology. 2011; 411(2):180-93. PMC: 3057271. DOI: 10.1016/j.virol.2010.12.004. View

4.
Li Z, Wolff K, Samuel C . RNA adenosine deaminase ADAR1 deficiency leads to increased activation of protein kinase PKR and reduced vesicular stomatitis virus growth following interferon treatment. Virology. 2009; 396(2):316-22. PMC: 2789878. DOI: 10.1016/j.virol.2009.10.026. View

5.
Hartmann G . Nucleic Acid Immunity. Adv Immunol. 2017; 133:121-169. PMC: 7112058. DOI: 10.1016/bs.ai.2016.11.001. View